HCR — Health Issues
Use of Section viii statements in pharmaceutical labeling. Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and legislation to reform pharmacy benefit managers. Patent reform legislation. Proposals related to drug shortages. Reauthorization of the Pandemic and All Hazards Preparedness Act (PAHPA). Proposals related to biosimilar drugs.
Government entities lobbied: Centers For Medicare and Medicaid Services (CMS); Executive Office of the President (EOP); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Homeland Security, Dept of (DHS); HOUSE OF REPRESENTATIVES; SENATE